sglt2 vs glp 1 vs dpp4 Renal outcomes of inhibitors and GLP1 agonists in clinical practice Prescribing pearls: A guide to

Improved Metabolic Control : They enhance insulin release when needed and reduce glucagon levels, balancing blood sugar and improving how the body uses energy

Clinicians should evaluate individual risk factors, comorbidities, and contraindications when choosing patients for treatment, balancing possible benefits with associated dangers

There are currently 4 DPP-4 inhibitors approved by the United States (U.S.) Food and Drug Administration (FDA): sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina)

"In theory, it's safe since it's an FDA-approved medication at a lower dose," said Tan

See on our website Claire de March, a researcher with flair Explore more Author Writes for CNRS Le Journal